PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

Chimeric antigen receptor (CAR) T‐cell therapy is a promising treatment option for relapsed or refractory (R/R) large B‐cell lymphoma (LBCL). However, only a subset of patients will present long‐term benefit. In this study, we explored the potential of PET‐based radiomics to predict treatment outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligero, Marta, Simó, Marc, Carpio, Cecilia, Iacoboni, Gloria, Balaguer‐Montero, Maria, Navarro, Victor, Sánchez‐Salinas, Mario Andres, Bobillo, Sabela, Marín‐Niebla, Ana, Iraola‐Truchuelo, Josu, Abrisqueta, Pau, Sala‐Llonch, Roser, Bosch, Francesc, Perez‐Lopez, Raquel, Barba, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Stem Cell Transplantation & Cellular Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660117/
https://www.ncbi.nlm.nih.gov/pubmed/38024636
http://dx.doi.org/10.1002/jha2.757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660117/
https://www.ncbi.nlm.nih.gov/pubmed/38024636
http://dx.doi.org/10.1002/jha2.757

Ejemplares similares